Krawczyk Noa, Feder Kenneth A, Fingerhood Michael I, Saloner Brendan
Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, 624 N. Broadway, Baltimore, MD, 21205, United States.
Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, 624 N. Broadway, Baltimore, MD, 21205, United States.
Drug Alcohol Depend. 2017 Sep 1;178:512-518. doi: 10.1016/j.drugalcdep.2017.06.009. Epub 2017 Jul 11.
Opioid Agonist Treatment (OAT) is the standard of care for the treatment of opioid use disorders. However, most people in treatment do not receive OAT. This study evaluated whether there are racial and/or ethnic differences in OAT receipt among adults entering specialty treatment for opioid use disorders in publicly-funded treatment programs across the U.S.
Using data from the national Treatment: Episode Data Base, odds of OAT receipt were compared among black, Hispanic and white clients. Mediation analyses were used to explore whether any racial/ethnic differences in OAT receipt were explained by variation in clinical need or by other treatment, sociodemographic, or geographic characteristics. Interaction terms were used to assess whether this association was modified by primary opioid type.
Only 28.7% of clients received OAT. Odds of OAT receipt were significantly higher odds among blacks (OR: 2.27(2.14-2.41)) and Hispanics (OR: 1.98(1.88-2.09)), compared to whites. Differences in clinical need accounted for a substantial portion of this difference (76.79% and 49.74%, respectively). Differences persisted after accounting for other potential explanatory variables (adjusted OR: 1.37 (1.24-1.52); 1.21(1.11-1.32)), but were only evident for primary heroin users (adjusted OR: 1.50 (1.34-1.69); 1.29 (1.17-1.42)) and not other opioid users.
OAT receipt in treatment programs is low overall and particularly lacking among white heroin users. Differences in OAT receipt cannot be fully explained by differences in clinical need. More research is needed to understand and address barriers that underpin these differences so more patients with opioid use disorder can access evidenced-based treatment.
阿片类激动剂治疗(OAT)是治疗阿片类物质使用障碍的标准治疗方法。然而,接受治疗的大多数人并未接受OAT。本研究评估了在美国公共资助治疗项目中进入阿片类物质使用障碍专科治疗的成年人在接受OAT方面是否存在种族和/或民族差异。
利用国家治疗:事件数据库的数据,比较了黑人、西班牙裔和白人患者接受OAT的几率。采用中介分析来探讨接受OAT方面的任何种族/民族差异是否由临床需求的差异或其他治疗、社会人口统计学或地理特征所解释。使用交互项来评估这种关联是否因主要阿片类药物类型而改变。
只有28.7%的患者接受了OAT。与白人相比,黑人(比值比:2.27(2.14 - 2.41))和西班牙裔(比值比:1.98(1.88 - 2.09))接受OAT的几率显著更高。临床需求的差异占这一差异的很大一部分(分别为76.79%和49.74%)。在考虑其他潜在解释变量后差异仍然存在(调整后的比值比:1.37(1.24 - 1.52);1.21(1.11 - 1.32)),但仅在主要使用海洛因的患者中明显(调整后的比值比:1.50(1.34 - 1.69);1.29(1.17 - 1.42)),其他阿片类药物使用者则不然。
治疗项目中OAT的接受率总体较低,在白人海洛因使用者中尤其缺乏。接受OAT方面的差异不能完全由临床需求的差异来解释。需要更多研究来理解和解决造成这些差异的障碍,以便更多阿片类物质使用障碍患者能够获得循证治疗。